REHOVOT, Israel and BRIDGEWATER, N.J., May 26, 2016 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that David Domzalski, President, will provide a corporate overview and business update at the Jefferies 2016 Healthcare Conference, taking place in New York City, New York, June 7-10, 2016.
Presentation Details:
Title:   Jefferies 2016 Healthcare Conference
Date:   Tuesday, June 7
Time:   11:30am Eastern Time
Location:   Grand Hyatt Hotel, New York City

About Foamix Pharmaceuticals Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.  The Company's clinical stage product candidates include FMX101, a novel minocycline foam for the treatment of moderate-to-severe acne, now in Phase 3 clinical studies, FMX102 for the treatment of impetigo, FMX103 for the treatment of rosacea, and FDX-104, a doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.  In addition, Foamix has development and license agreements relating to its technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Prestium.

For more information, please visit

Contact:Dorit Hayon, BDFoamix Pharmaceuticals Ltd.+972-8-9316233IR@foamixpharma.comUS Investor RelationsMichael RiceLifeSci Advisors,

Primary Logo